The Claim
A 50% reduction in the price of semaglutide could result in an incremental cost-effectiveness ratio of $37,190 per quality-adjusted life year (QALY) gained, with an 80% probability of being cost-effective at a $50,000 per QALY willingness-to-pay threshold in a modeled population of overweight or obese adults with cardiovascular disease and no diabetes.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If the price of semaglutide is cut in half, it might become a good value for treating people with heart disease who are overweight or obese—even if they don’t have diabetes—because it could add healthy years of life for less than $50,000 per year of quality life gained.
See the scientific wording
Reducing the price of semaglutide by 50% could improve its cost-effectiveness profile to $37,190 per quality-adjusted life year (QALY) gained, with an 80% probability of being cost-effective at a $50,000 per QALY willingness-to-pay threshold in a modeled population of overweight or obese adults with cardiovascular disease and no diabetes.
What the research says
1 studyStudy: Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
The study looked at lowering the price of semaglutide by half and found it would likely be a good value for healthcare systems, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.